Theravance and Merck ink hypertension, heart failure deal

Editorial Staff | October 17, 2012 | Cardiovascular Business | Structural Heart Disease

Theravance has signed a collaboration agreement with Merck to develop and commercialize new small molecule therapeutics directed toward a target being investigated for the treatment of hypertension and heart failure.

In exchange for granting Merck a worldwide, exclusive license to its therapeutic candidates, San Francisco-based Theravance will receive a $5 million upfront payment, funding for research, and be eligible for milestone payments totaling up to $148 million for the first indication and royalties on worldwide net sales of any products derived from the collaboration.

Theravance currently develops and commercializes small molecule medicines across therapeutic areas, including respiratory diseases, bacterial infections and central nervous system/pain.

Editorial Staff

Around the web

Radiology Business

Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging

Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Theravance and Merck ink hypertension, heart failure deal

Related Content

Around the web